1 Min Read
NEW YORK, Sept 24 (Reuters) - Peregrine Pharmaceuticals Inc : * Pharma drops 71.2 percent to $1.55 in premarket after discrepancies discovered in bavituximab trial data
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.